GlassScriptPhysician profile
Jose Martinez
NPI 1508853490
$10,514.11
in general payments reported to CMS, 2019-2025
38 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $1,146 · 2021: $1,833 · 2022: $1,759 · 2023: $1,670 · 2024: $1,583 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.03 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,195.33 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $1,975.79 | 2019-2025 | |
| Janssen Biotech, INC. | $956.50 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Qol Medical, LLC | $874.74 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $667.39 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $498.35 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $496.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Grifols USA, LLC | $457.81 | 2019-2024 | Prolastin-C Liquid |
| Janssen Scientific Affairs, LLC | $241.76 | 2021-2022 | |
| Redhill Biopharma INC. | $230.71 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Nestle Healthcare Nutrition INC. | $209.41 | 2020-2021 | |
| Braintree Laboratories, INC. | $183.38 | 2019-2025 | Sutab, Suflave |
| Innovation Technologies INC | $181.91 | 2024 | Irrisept |
| Ipsen Biopharmaceuticals, INC | $179.08 | 2024 | Iqirvo |
| Celgene Corporation | $158.81 | 2021-2024 | Zeposia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.